NEWS

In May, 2025, Scientific Advisory Group of Chemical Safety of Non-food and Non-medicinal Consumer Products (SAG-CS) issued opinion on Homosalate in Cosmetics (Opinion 17).

On May, 2025, Scientific Advisory Group of Chemical Safety of Non-food and Non-medicinal Consumer Products (SAG-CS) issued opinion on formaldehyde releasing substances (Opinion 16).

On June 24, 2025, the National Institutes for Food and Drug Control (NIFDC) released two technical guidelines-Guideline for the Study and Determination of the History of Safe Consumption of New Cosmetic Ingredients (Trial) and Guideline for the Study and Determination of the History of Safe Use of New Cosmetic Ingredients (Trial)-along with related Q&As. Following six questions together with the corresponding answers are related to the second guideline. CIRS Group has compiled and translated them into English for your reference.

On June 24, 2025, the National Institutes for Food and Drug Control (NIFDC) released two technical guidelines-Guideline for the Study and Determination of the History of Safe Consumption of New Cosmetic Ingredients (Trial) and Guideline for the Study and Determination of the History of Safe Use of New Cosmetic Ingredients (Trial)-along with related Q&As. Following six questions together with the corresponding answers are related to the second guideline. CIRS Group has compiled and translated them into English for your reference.

In June 2025, CIRS Group once again assisted in the successful filing of a new cosmetic ingredient--Defensamide (Filing No.: GZYBZ*20250070), and the filing was submitted under Scenario 3. The filer is NeoPharm Co., Ltd. To date, the Personal and Home Care Division of CIRS Group has supported dozens of companies in securing new cosmetic ingredient filing numbers in China, and continues to provide technical support throughout the monitoring period.

Based on data retrieved from China’s National Medical Products Administration (NMPA), three new cosmetic ingredients were successfully filed between June 16 and June 18, 2025. Detailed information is provided in the table below. At present, the associated technical specifications have not been made public, and the ingredient has not yet entered the post-filing monitoring period.

This article compiles and summarizes the latest developments in cosmetics regulations in China and globally as of May 2025, covering industry news, newly issued regulations, relevant policy adjustments, and regulatory requirements. It aims to assist enterprises in ensuring compliance and keeping up with global cosmetics regulatory trends.

In order to strengthen cosmetic regulation and safeguard consumer rights, the NMPA's Department of Cosmetics Supervision has provided answers to key industry concerns-such as labeling-based on current Chinese laws and technical standards. CIRS Group has compiled the information and translated them into English for your reference.

Following FAQs are all related to cosmetic safety assessment, CIRS Group has compiled the information and translated them into English for your reference.

On June 6, 2025, the Scientific Committee on Consumer Safety (SCCS) of the European Union issued a preliminary opinion (SCCS/1680/25) on Prostaglandin Analogues: Methylamido-Dihydro-Noralfaprostal (MDN) (CAS No. 155206-01-2), Isopropyl Cloprostenate (IPCP) (CAS No. 157283-66-4) and Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE) (CAS No. 1185851-52-8). The deadline for comments is set for August 18, 2025.